Canlyniadau Chwilio - Thomas Bohnacker

  • Dangos 1 - 10 canlyniadau o 10
Mireinio'r Canlyniadau
  1. 1
    Fluid-Phase Pinocytosis of Native Low Density Lipoprotein Promotes Murine M-CSF Differentiated Macrophage Foam Cell Formation

    Fluid-Phase Pinocytosis of Native Low Density Lipoprotein Promotes Murine M-CSF Differentiated Macrophage Foam Cell Formation gan Manoj Kumar Barthwal, Joshua J. Anzinger, Qing Xu, Thomas Bohnacker, Matthias P. Wymann, Howard S. Kruth

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    PKCβ Phosphorylates PI3Kγ to Activate It and Release It from GPCR Control

    PKCβ Phosphorylates PI3Kγ to Activate It and Release It from GPCR Control gan Romy Walser, John E. Burke, Elena Gogvadze, Thomas Bohnacker, Xuxiao Zhang, Daniel Heß, Peter Küenzi, Michael Leitges, Emilio Hirsch, Roger Williams, Muriel Laffargue, Matthias P. Wymann

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors

    Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors gan Romina Marone, Dominik Erhart, Ann C. Mertz, Thomas Bohnacker, Christian Schnell, Vladimir Cmiljanović, Frédéric Stauffer, Carlos Garcı́a-Echeverrı́a, Bernd Giese, Sauveur-Michel Maira, Matthias P. Wymann

    Cyhoeddwyd 2009
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Ras is an indispensable coregulator of the class I <sub>B</sub> phosphoinositide 3-kinase p87/p110γ

    Ras is an indispensable coregulator of the class I <sub>B</sub> phosphoinositide 3-kinase p87/p110γ gan Barbara Kurig, Aliaksei Shymanets, Thomas Bohnacker, Prajwal Prajwal, Carsten Brock, Mohammad Reza Ahmadian, Michael Schaefer, Antje Gohla, Christian Harteneck, Matthias P. Wymann, Elisabeth Jeanclos, Bernd Nürnberg

    Cyhoeddwyd 2009
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor

    A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor gan Chiara Borsari, Denise Rageot, Alix Dall’Asen, Thomas Bohnacker, Anna Melone, Alexander Sele, Eileen Jackson, Jean‐Baptiste Langlois, Florent Beaufils, Paul Hebeisen, Doriano Fabbro, Petra Hillmann, Matthias P. Wymann

    Cyhoeddwyd 2019
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders

    Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and... gan Denise Rageot, Thomas Bohnacker, Anna Melone, Jean‐Baptiste Langlois, Chiara Borsari, Petra Hillmann, Alexander Sele, Florent Beaufils, Marketa Zvelebil, Paul Hebeisen, Wolfgang Löscher, John E. Burke, Doriano Fabbro, Matthias P. Wymann

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    (<i>S</i>)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase

    (<i>S</i>)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor... gan Denise Rageot, Thomas Bohnacker, Erhan Keleş, Jacob A. McPhail, Reece M. Hoffmann, Anna Melone, Chiara Borsari, Rohitha Sriramaratnam, Alexander Sele, Florent Beaufils, Paul Hebeisen, Doriano Fabbro, Petra Hillmann, John E. Burke, Matthias P. Wymann

    Cyhoeddwyd 2019
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

    5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Can... gan Florent Beaufils, Nataša Cmiljanović, Vladimir Cmiljanović, Thomas Bohnacker, Anna Melone, Romina Marone, Eileen Jackson, Xuxiao Zhang, Alexander Sele, Chiara Borsari, Jürgen Mestan, Paul Hebeisen, Petra Hillmann, Bernd Giese, Marketa Zvelebil, Doriano Fabbro, Roger Williams, Denise Rageot, Matthias P. Wymann

    Cyhoeddwyd 2017
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease

    New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease gan Luca Aresu, Serena Ferraresso, Laura Marconato, Luciano Cascione, Sara Napoli, Eugenio Gaudio, Ivo Kwee, Chiara Tarantelli, Andrea Testa, Chiara Maniaci, Alessio Ciulli, Petra Hillmann, Thomas Bohnacker, Matthias P. Wymann, S. Comazzi, Massimo Milan, Fulvio Riondato, Giulia Dalla Rovere, Mery Giantin, Diana Giannuzzi, Francesco Bertoni

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Carta
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention

    Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention gan Thomas Bohnacker, A.E. Prota, Florent Beaufils, John E. Burke, Anna Melone, Alison J. Inglis, Denise Rageot, Alexander Sele, Vladimir Cmiljanović, Nataša Cmiljanović, Katja Bargsten, Amol Aher, Anna Akhmanova, J. Fernando Dı́az, Doriano Fabbro, Marketa Zvelebil, Roger Williams, Michel O. Steinmetz, Matthias P. Wymann

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: